madman
Super Moderator
Is it the TRAVERSE Trial or a Travesty?
There is a paper published that did not put its limitations into perspective and may lead to false reassurance about the safety of testosterone, recently published in the New England Journal of Medicine.1 This trial was done to demonstrate cardiovascular safety of testosterone repletement in men...
www.excelmale.com
TRT and cardiovascular risk: TRAVERSE with caution
The relationship between testosterone replacement therapy (TRT) and cardiovascular(CV) disease (CVD) risk in older, hypogonadal men has been debated for years. Observational studies have variably linked low endogenous testosterone levels with adverse cardio metabolic effects and increased CVD...
www.excelmale.com
*We bring attention to the limitations of the TRAVERSE trial due to the potential for misleading reassurance of the safety of TRT at physiologic or supraphysiologic levels. The long term CV effects and the safety of such regimens have yet to be studied. We certainly advocate for further research to explore the long-term CV impact of TRT, especially at these higher dosing levels.
*The debate surrounding TRT and CVD risk thus far can be summarized as follows: current evidence suggests TRT does not increase CVD risk in older, hypogonadal men when administered over a short duration and at low-normal levels of replacement. The question remains open when considering the effects of TRT at physiologic or supraphysiologic levels.
